JP5539324B2 - 細胞死を検出しイメージングするための薬剤 - Google Patents

細胞死を検出しイメージングするための薬剤 Download PDF

Info

Publication number
JP5539324B2
JP5539324B2 JP2011506768A JP2011506768A JP5539324B2 JP 5539324 B2 JP5539324 B2 JP 5539324B2 JP 2011506768 A JP2011506768 A JP 2011506768A JP 2011506768 A JP2011506768 A JP 2011506768A JP 5539324 B2 JP5539324 B2 JP 5539324B2
Authority
JP
Japan
Prior art keywords
contrast agent
individual
treatment
cells
c2am
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011506768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519367A (ja
JP2011519367A5 (enExample
Inventor
ブリンドル，ケビン
ニーブス，アンドレ
バッカー，マアイケ デ
アラム，イスラット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2011519367A publication Critical patent/JP2011519367A/ja
Publication of JP2011519367A5 publication Critical patent/JP2011519367A5/ja
Application granted granted Critical
Publication of JP5539324B2 publication Critical patent/JP5539324B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2011506768A 2008-04-29 2009-04-29 細胞死を検出しイメージングするための薬剤 Expired - Fee Related JP5539324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0807831.3A GB0807831D0 (en) 2008-04-29 2008-04-29 Agents for imaging cell death
GB0807831.3 2008-04-29
PCT/GB2009/001082 WO2009133362A2 (en) 2008-04-29 2009-04-29 Agents for detecting and imaging cell death

Publications (3)

Publication Number Publication Date
JP2011519367A JP2011519367A (ja) 2011-07-07
JP2011519367A5 JP2011519367A5 (enExample) 2012-06-07
JP5539324B2 true JP5539324B2 (ja) 2014-07-02

Family

ID=39522785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506768A Expired - Fee Related JP5539324B2 (ja) 2008-04-29 2009-04-29 細胞死を検出しイメージングするための薬剤

Country Status (6)

Country Link
US (1) US8685371B2 (enExample)
EP (1) EP2280735B1 (enExample)
JP (1) JP5539324B2 (enExample)
CA (1) CA2722914A1 (enExample)
GB (1) GB0807831D0 (enExample)
WO (1) WO2009133362A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
WO2011142858A2 (en) * 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
EP2575897A4 (en) * 2010-06-01 2016-06-01 Advanced Proteome Therapeutics Inc CROSSLINKING OF PROTEINS AND OTHER ENTITIES THROUGH ALPHA-HALO-ACETOPHENONES CONJUGATES, BENZYL HALIDES, QUINONES
US20140179560A1 (en) 2012-12-10 2014-06-26 Fred Hutchinson Cancer Research Center Drug discovery methods and platforms
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
AU2018210912A1 (en) * 2017-01-17 2019-08-15 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
WO2020014639A1 (en) * 2018-07-12 2020-01-16 Beckman Coulter, Inc. Fixable viability dyes and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022731A1 (en) 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
US20060110323A1 (en) 2004-11-19 2006-05-25 Ming Zhao Method of imaging cell death in vivo
US8506928B2 (en) * 2007-09-07 2013-08-13 The Regents Of The University Of California Methods and compounds for targeting tissues

Also Published As

Publication number Publication date
GB0807831D0 (en) 2008-06-04
JP2011519367A (ja) 2011-07-07
WO2009133362A3 (en) 2010-03-25
WO2009133362A2 (en) 2009-11-05
EP2280735A2 (en) 2011-02-09
EP2280735B1 (en) 2015-09-23
US8685371B2 (en) 2014-04-01
US20110038798A1 (en) 2011-02-17
CA2722914A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
JP5539324B2 (ja) 細胞死を検出しイメージングするための薬剤
ES2787099T3 (es) Fucoidanos como ligandos para el diagnóstico de patologías degenerativas
US9675715B2 (en) Contrast agent for photoacoustic imaging
AU2009205950B2 (en) Fluorescent imaging agents
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
EP2831264A1 (en) Bacterial imaging agents and methods of using same
CN104955484A (zh) 用于前列腺癌成像的前列腺特异性抗原药剂及其使用方法
EP3072530B1 (en) Near-infrared dye-bound transferrin, and contrast agent for photoacoustic imaging, including the near-infrared dye-bound transferrin
JP6177036B2 (ja) 光音響イメージング用造影剤
US11890352B2 (en) Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
US20140363378A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
US20170224833A1 (en) Self-assembling molecules that accumulate in acidic tumor microenvironments
JP6395880B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
JP6099055B2 (ja) 変性病変の診断のためのリガンドとしてのフコイダン
Langel Methods for Molecular Imaging, Detection and Visualization of CPPs
HK40073647A (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
Guerrero Virus-Resembling Nano-Structures for Fluorescence Imaging of Ovarian Cancer
WO2018037996A1 (ja) グルタミントランスポーターと多価結合することができるリガンド、及び当該リガンドを含む組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131205

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140401

R150 Certificate of patent or registration of utility model

Ref document number: 5539324

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140430

LAPS Cancellation because of no payment of annual fees